266 related articles for article (PubMed ID: 1510710)
21. Role of CYP2D6 in the N-hydroxylation of procainamide.
Lessard E; Fortin A; Bélanger PM; Beaune P; Hamelin BA; Turgeon J
Pharmacogenetics; 1997 Oct; 7(5):381-90. PubMed ID: 9352574
[TBL] [Abstract][Full Text] [Related]
22. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6).
Tucker GT; Lennard MS; Ellis SW; Woods HF; Cho AK; Lin LY; Hiratsuka A; Schmitz DA; Chu TY
Biochem Pharmacol; 1994 Mar; 47(7):1151-6. PubMed ID: 7909223
[TBL] [Abstract][Full Text] [Related]
23. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
Prueksaritanont T; Dwyer LM; Cribb AE
Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
[TBL] [Abstract][Full Text] [Related]
24. Complementary DNA cloning and characterization of cytochrome P450 2D29 from Japanese monkey liver.
Hichiya H; Takemi C; Tsuzuki D; Yamamoto S; Asaoka K; Suzuki S; Satoh T; Shinoda S; Kataoka H; Narimatsu S
Biochem Pharmacol; 2002 Oct; 64(7):1101-10. PubMed ID: 12234613
[TBL] [Abstract][Full Text] [Related]
25. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.
Kudo S; Odomi M
Eur J Clin Pharmacol; 1998 May; 54(3):253-9. PubMed ID: 9681669
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
Masubuchi Y; Hosokawa S; Horie T; Suzuki T; Ohmori S; Kitada M; Narimatsu S
Drug Metab Dispos; 1994; 22(6):909-15. PubMed ID: 7895609
[TBL] [Abstract][Full Text] [Related]
27. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
28. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
Tyndale RF; Sunahara R; Inaba T; Kalow W; Gonzalez FJ; Niznik HB
Mol Pharmacol; 1991 Jul; 40(1):63-8. PubMed ID: 1857341
[TBL] [Abstract][Full Text] [Related]
29. Optimization of yeast-expressed human liver cytochrome P450 3A4 catalytic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome b5.
Peyronneau MA; Renaud JP; Truan G; Urban P; Pompon D; Mansuy D
Eur J Biochem; 1992 Jul; 207(1):109-16. PubMed ID: 1628642
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes.
Bellec G; Dréano Y; Lozach P; Ménez JF; Berthou F
Carcinogenesis; 1996 Sep; 17(9):2029-34. PubMed ID: 8824531
[TBL] [Abstract][Full Text] [Related]
31. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
32. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
33. Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan.
Rodrigues AD; Kukulka MJ; Surber BW; Thomas SB; Uchic JT; Rotert GA; Michel G; Thome-Kromer B; Machinist JM
Anal Biochem; 1994 Jun; 219(2):309-20. PubMed ID: 8080088
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
Sanwald P; David M; Dow J
Drug Metab Dispos; 1996 May; 24(5):602-9. PubMed ID: 8723743
[TBL] [Abstract][Full Text] [Related]
35. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
[TBL] [Abstract][Full Text] [Related]
36. Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).
Pressacco J; Muller R; Kalow W
Eur J Clin Pharmacol; 1993; 45(3):261-4. PubMed ID: 8276051
[TBL] [Abstract][Full Text] [Related]
37. Transgenic yeast expressing human cytochrome P450s can serve as a tool in studies of the mechanisms of their induction by various effectors.
Kovaleva IE; Krynetskii EY; Luzikov VN
Biochem Biophys Res Commun; 1996 Apr; 221(1):129-32. PubMed ID: 8660322
[TBL] [Abstract][Full Text] [Related]
38. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity.
Wan J; Imaoka S; Chow T; Hiroi T; Yabusaki Y; Funae Y
Arch Biochem Biophys; 1997 Dec; 348(2):383-90. PubMed ID: 9434752
[TBL] [Abstract][Full Text] [Related]
39. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
40. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
